Impact Factor
3.94
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.78
953 total citations
h5-index
33
h5 depth signal
Cited share
89.2%
181 of 203
Total citations
953
Citation footprint
Metric signal
6.72
External metric anchor
Self-citation
1.2%
11 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
621
Canada
63
United Kingdom
54
Italy
50
Germany
39
Citing Fields of Research
Hematology
662
Lymphomas
229
Immunology
93
Oncology
51
Cardiology
40
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,233
Articles tracked across the journal lifetime
Indexed publication set
203
181 cited publications
Last 12 months
89
89.0 publications/month
Open access share
0.0%
0 OA publications in the last year
Leading citing country
United States
621 citing publications
Leading citing field
Hematology
662 citing publications
Latest tracked publication
5 December 2025
10 recent records available
Coverage & Indexing History
2001-
2001-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Hematology
Lymphomas
Issuing & Sponsoring Bodies
Contributor
American Society of Hematology. Education Program
Broad Categories
Hematology
Lymphomas
MeSH Descriptors
Hematologic Diseases
Hematology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1182/hematology.2025000692
Open DOI
Iron toxicity and hematopoietic cell transplantation: do we understand why iron affects transplant outcome?
In the last decades, we have witnessed huge progress in the understanding of iron metabolism and the consequences of its dysregulation in case of overload, and we have understood how, in the case of hematopoietic transplantation, the tox...
02
DOI 10.1182/hematology.2025000691
Open DOI
Management of iron overload in adult myelodysplastic syndrome
The clinical benefits of iron overload (IOL) management in hereditary anemias, including organ preservation and dramatically improved overall survival (OS), are widely accepted. Adult myelodysplastic syndrome (MDS) patients are older and...
03
DOI 10.1182/hematology.2025000690
Open DOI
No shots needed: direct oral anticoagulants in cancer-associated thrombosis—10-year follow-up
Active malignancy is a known prothrombotic state, first described by Armand Trousseau as thrombophlebitis occurring in a patient with metastatic gastric cancer. The most common presentation of cancer-associated thrombosis (CAT) is venous...
04
DOI 10.1182/hematology.2025000743
Open DOI
A practical approach to immune thrombocytopenia in pregnancy
Immune thrombocytopenia (ITP) often presents for the first time in pregnancy, or, in patients with a history of ITP, pregnancy can trigger a relapse. ITP in pregnancy is often mild, leading to minimal or no symptoms; however, treatment m...
05
DOI 10.1182/hematology.2025000740
Open DOI
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma
The advent of T-cell redirecting strategies, including chimeric antigen receptor T cells and bispecific antibodies, has significantly improved the prognosis of patients with relapsed/refractory large B-cell lymphoma. Current, ongoing cli...
06
DOI 10.1182/hematology.2025000729
Open DOI
POEMS syndrome: diagnosis, treatments, and outcomes
POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome is a complex paraneoplastic syndrome related to a lambda-restricted low–tumor burden neoplasm. The diagnosis must be considered in the context of what...
07
DOI 10.1182/hematology.2025000702
Open DOI
Update in the diagnosis of complement-mediated thrombotic microangiopathy/atypical hemolytic uremic syndrome
Complement-mediated thrombotic microangiopathy (C-TMA), also referred to as atypical hemolytic uremic syndrome (aHUS), is a rare but severe cause of microangiopathic hemolysis and organ injury. Despite advances in understanding its patho...
08
DOI 10.1182/hematology.2025000698
Open DOI
What's new in hereditary hemorrhagic telangiectasia?
Hereditary hemorrhagic telangiectasia (HHT) is an inherited vasculopathy that results in dysregulated angiogenesis leading to the development of mucocutaneous telangiectasias and visceral organ arteriovenous malformations. HHT is the sec...
09
DOI 10.1182/hematology.2025000750
Open DOI
When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?
Plasmablastic lymphoma (PBL) is a rare and aggressive, usually CD20-negative, B-cell lymphoma with features between multiple myeloma and diffuse large B-cell lymphoma. Approximately 120 new cases are diagnosed annually in the United Stat...
10
DOI 10.1182/hematology.2025000748c
Open DOI
All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?
Mediastinal gray zone lymphoma (MGZL) is defined in the international World Health Organization classification as a B-cell lymphoma with overlapping clinical, morphological, immunophenotypic, and molecular features between primary medias...
Bibliographical & Catalog Notes
Description based on: 1995.
Also issued online.